Su Jin Lim, ScM


Su Jin received my ScM in Biostatistics from Johns Hopkins University in 2018. Prior to the QSU, she was a biostatistician in the Division of Quantitative Sciences at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. During her time at Johns Hopkins, she closely collaborated with investigators, providing statistical support for their early phase clinical trials and cancer research, with a focus on gastrointestinal and prostate cancer.

Clinical Area of Interests: oncology, radiology, pedatrics, and infectious disease

Methodology Area of Interests: clinical trial designs, medical image analysis, machine learning and data visualization

Selected Publications: 

  1. Wilbur HC, Durham JN, Lim SJ, Purtell K, Bever KM, Laheru DA, De Jesus-Acosta A, Azad NS, Wilt B, Diaz LA, Le DT, Wang H. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Cancer Res Commun. 2023 Aug 28;3(8):1672-1677. doi: 10.1158/2767-9764.CRC-23-0230. PMID: 37645623; PMCID: PMC10461640
  2. Heumann T, Judkins C, Li K, Lim SJ, Hoare J, Parkinson R, Cao H, Zhang T, Gai J, Celiker B, Zhu Q, McPhaul T, Durham J, Purtell K, Klein R, Laheru D, De Jesus-Acosta A, Le DT, Narang A, Anders R, Burkhart R, Burns W, Soares K, Wolfgang C, Thompson E, Jaffee E, Wang H, He J, Zheng L. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun. 2023 Jun 20;14(1):3650. doi: 10.1038/s41467-023-39196-9. PMID: 37339979; PMCID: PMC10281953.
  3. Pflu ̈ger MJ, Jamouss KT, Afghani E, Lim SJ, Rodriguez Franco S, Mayo H, Spann M, Wang H, Singhi A, Lennon AM, Wood LD. Predictive ability of pancreatic cyst fluid biomarkers: A systematic review and meta-analysis. Pancreatology. 2023 May 15:S1424-3903(23)00142-4. doi: 10.1016/j.pan.2023.05.005. Epub ahead of print. PMID: 37230894.
  4. Wang H, Berger KN, Miller EL, Fu W, Broglie L, Goldman FD, Konig H, Lim SJ, Berg AS, Talano JA, Comito MA, Farag SS, Pu JJ. The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation. Ther Adv Hematol. 2023 May 3;14:20406207231170708. doi: 10.1177/20406207231170708. PMID: 37151808; PMCID: PMC10161310.
  5. Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, Ji H, Allaf ME, Chapman C, Moore PA, Chen F, Sorg K, White AM, Church SE, Hudson B, Fields PA, Hu S, Denmeade SR, Pienta KJ, Pavlovich CP, Ross AE, Drake CG, Pardoll DM, Antonarakis ES. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med. 2023 Apr;29(4):888-897. doi: 10.1038/s41591-023-02284-w. Epub 2023 Apr 3. PMID: 37012549.
  6. Denmeade S, Lim SJ, Isaaccson Velho P, Wang H. PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study. Prostate. 2022 Dec;82(16):1529-1536. doi: 10.1002/pros.24426. Epub 2022 Aug 8. PMID: 35938545; PMCID: PMC9633380.
  7. Li K, Tandurella JA, Gai J, Zhu Q, Lim SJ, Thomas DL 2nd, Xia T, Mo G, Mitchell JT, Montagne J, Lyman M, Danilova LV, Zimmerman JW, Kinny-K ̈oster B, Zhang T, Chen L, Blair AB, Heumann T, Parkinson R, Durham JN, Narang AK, Anders RA, Wolfgang CL, Laheru DA, He J, Osipov A, Thompson ED, Wang H, Fertig EJ, Jaffee EM, Zheng L. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. 2022 Nov 14;40(11):1374-1391.e7. doi: 10.1016/j.ccell.2022.10.001. Epub 2022 Oct 27. PMID: 36306792; PMCID: PMC9669212.
  8. Christenson ES, Lim SJ, Durham J, De Jesus-Acosta A, Bever K, Laheru D, Ryan A, Agarwal P, Scharpf RB, Le DT, Wang H. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Res Commun. 2022 Nov 11;2(11):1418-1425. doi: 10.1158/2767-9764.CRC-22-0343. PMID: 36970054; PMCID: PMC10035498.
  9. Nizialek E, Lim SJ, Wang H, Isaacsson Velho P, Yegnasubramanian S, Antonarakis ES. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. Prostate. 2021 Jun;81(9):572-579. doi: 10.1002/pros.24135. Epub 2021 May 6. PMID: 33955569.
  10. Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 Apr 20;39(12):1371-1382. doi: 10.1200/JCO.20.02759. Epub 2021 Feb 22. PMID: 33617303; PMCID: PMC8274807.